APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology

Abstract excerpt

BACKGROUND: Apolipoprotein E ε4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD). A recent case report identified a rare variant in APOE, APOE3-R136S (Christchurch), proposed to confer resistance to autosomal dominant Alzheimer's Disease (AD). However, it remains unclear whether and how this variant exerts its protective effects. METHODS: We introduced the R136S variant into...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alzheimer's disease research and treatments
• Share to Dementia and Cognitive Impairment Research
• Share to Neuroinflammation and Neurodegeneration Mechanisms